Netuka I 1
1. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): third Paediatric (Paedi-EUROMACS) report
2. The European Registry for Patients with Mechanical Circulatory Support of the European Association for Cardio-Thoracic Surgery: third report
3. Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis
4. Aspirin and Hemocompatibility after LVAD Implantation in Patients with Atherosclerotic Vascular Disease: A Secondary Analysis from the ARIES-HM3 Randomized Clinical Trial
5. Impact of concomitant cardiac valvular surgery during implantation of continuous-flow left ventricular assist devices: A European registry for patients with mechanical circulatory support (EUROMACS) analysis
6. Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial
7. First 5-year multicentric clinical trial experience with the HeartMate 3 left ventricular assist system
8. First Clinical Experience With the Pressure Sensor-Based Autoregulation of Blood Flow in an Artificial Heart
9. Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy
10. Bioprosthetic Total Artificial Heart Implantation Does Not Induce Chronic Inflammation
11. Bioprosthetic Total Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor
12. Progressive endothelial coverage enhances hemocompatibility and prevents calcification in bioprosthetic valve tissue
13. Propensity score-based analysis of long-term follow-up in patients supported with durable centrifugal left ventricular assist devices: The EUROMACS analysis
14. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): fourth Paediatric EUROMACS (Paedi-EUROMACS) report
15. Five-year outcomes of patients supported with HeartMate 3: A single-centre experience
16. Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation
17. Understanding Platelet Activation in the Aeson Bioprosthetic Total Artificial Heart: Insights From Aspirin Treatment and Outcomes
18. Impact of Atrial Fibrillation, Diabetes Mellitus, and Obesity on Outcomes With Aspirin Avoidance and Hemocompatibility With a Left Ventricular Assist Device: An Analysis From the ARIES-HM3 Trial
19. The fourth report of the European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardiothoracic Surgery: focus on standardized outcome ratios
20. Implantation Technique for the Aeson Total Artificial Heart
1